metformin has been researched along with Uterine Cervical Neoplasms in 25 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Uterine Cervical Neoplasms: Tumors or cancer of the UTERINE CERVIX.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin decreased cervical tumor hypoxia in this trial that selected for patients with hypoxic tumor." | 5.51 | A Phase II Randomized Trial of Chemoradiation with or without Metformin in Locally Advanced Cervical Cancer. ( Bruce, J; Cairns, R; Chaudary, N; Croke, J; D'Souza, D; Dhani, N; Fyles, A; Han, K; Jaffray, D; Koritzinsky, M; Lee, TY; Metser, U; Milosevic, M; Pakbaz, S; Pintilie, M; Rouzbahman, M; Shek, T; Vines, D, 2022) |
| "Metformin has been demonstrated to reduce cell-viability post-radiotherapy in both rectal and prostate cancer cell lines, with an enhanced effect in tumours with a p53 mutation and increased apoptosis post-radiotherapy for cervical cancer." | 2.72 | Metformin as a radiosensitiser for pelvic malignancy: A systematic review of the literature. ( Clifford, RE; Fok, M; Gerrard, AD; Vimalachandran, D, 2021) |
| "Modulation of AMPK may have a role in cervical cancer treatment." | 1.91 | Radiosensitising Effects of Metformin Added to Concomitant Chemoradiotherapy with Cisplatin in Cervical Cancer. ( Beduk Esen, CS; Canpinar, H; Gedik, ME; Gultekin, M; Gunaydin, G; Yedekci, FY; Yildiz, F, 2023) |
| "The occurrence of cervical cancer was explored by matching for age, economic status, region of residence, and use of anti-diabetic medication." | 1.72 | Metformin and Cervical Cancer Risk in Patients with Newly Diagnosed Type 2 Diabetes: A Population-Based Study in Korea. ( Kang, MJ; Kim, HM; Song, SO, 2022) |
| "Human cervical cancer is the fourth most common malignancy among women worldwide, and it is expected to result in 460,000 deaths per year by 2040." | 1.62 | Metformin induces apoptosis and inhibits migration by activating the AMPK/p53 axis and suppressing PI3K/AKT signaling in human cervical cancer cells. ( Chen, TH; Chen, YH; Chou, MC; Hsiao, YH; Tsai, HD; Yang, CK; Yang, SF, 2021) |
| "Metformin can inhibit the PI3K/Akt signaling pathway and synergizes with Nelfinavir to inhibit the proliferation and invasion of cervical cancer cells." | 1.56 | iTRAQ-based quantitative proteomic analysis of the inhibition of cervical cancer cell invasion and migration by metformin. ( Cai, Y; He, Z; Xia, C; Yang, F, 2020) |
| "Metformin inhibited cervical cancer cell proliferation, cervical cancer xenograft growth, expression of PCNA, p-PI3K and p-Akt." | 1.56 | Metformin inhibits cervical cancer cell proliferation by modulating PI3K/Akt-induced major histocompatibility complex class I-related chain A gene expression. ( Cai, Y; Chen, J; He, Z; Liu, C; Xia, C, 2020) |
| "Metformin displays antimigration effects in cervical cancer cells by inhibiting filopodia and lamellipodia formation through the suppression of FAK, Akt and its downstream Rac1 and RhoA protein." | 1.51 | Metformin Inhibit Cervical Cancer Migration by Suppressing the FAK/Akt Signaling Pathway. ( Chonpathompikunlert, P; Hakimee, H; Hutamekalin, P; Sukketsiri, W; Tanasawet, S; Tipmanee, V, 2019) |
| "The molecular mechanisms underlying the antineoplastic properties of metformin combined with nelfinavir remain elusive." | 1.51 | Metformin combined with nelfinavir induces SIRT3/mROS-dependent autophagy in human cervical cancer cells and xenograft in nude mice. ( Chen, R; He, Z; Jiang, S; Liang, S; Xia, C; Xiao, G; Xu, W; Yang, J, 2019) |
| "We found that metformin could suppress cervical cancer migration and invasion." | 1.48 | Metformin, a first-line drug for type 2 diabetes mellitus, disrupts the MALAT1/miR-142-3p sponge to decrease invasion and migration in cervical cancer cells. ( Chen, J; Chen, R; He, Z; Liang, S; Xia, C; Zhu, X, 2018) |
| "In order to improve the sensitivity of cervical cancer cells to irradiation therapy, we targeted hexokinase 2 (HK2), the first rate-limiting enzyme of glycolysis, and explore its role in cervical cancer cells." | 1.46 | Targeting hexokinase 2 inhibition promotes radiosensitization in HPV16 E7-induced cervical cancer and suppresses tumor growth. ( Casero, RA; Che, Q; Jiang, F; Jin, L; Kagiampakis, I; Ke, J; Liu, Y; Murray-Stewart, T; Tong, H; Wan, X; Wang, F; Wang, H; Zhang, J, 2017) |
| "Metformin users were more likely to be older, hypertensive, diabetic, and dyslipidemic compared with nonusers (all, P < 0." | 1.46 | Association of Metformin Use and Survival Outcome in Women With Cervical Cancer. ( Brunette, LL; Frimer, M; Hom, MS; Machida, H; Matsuo, K; Mostofizadeh, S; Takiuchi, T, 2017) |
| "Human cervical cancer is the fourth most common carcinoma in women worldwide." | 1.46 | Combining metformin and nelfinavir exhibits synergistic effects against the growth of human cervical cancer cells and xenograft in nude mice. ( Chen, J; Chen, R; Du, L; Jiang, S; Pan, Y; Qi, Q; Xia, C; Xiao, G, 2017) |
| "Among the 181 women with diabetes and cervical cancer, there were 129 deaths, including 61 cervical cancer-specific deaths." | 1.43 | Association between Metformin Use and Mortality after Cervical Cancer in Older Women with Diabetes. ( Fyles, AW; Han, K; Lega, IC; Lipscombe, LL; Milosevic, MF; Pintilie, M, 2016) |
| "Patients with early stage cervical cancer diagnosed between 2001 and 2014 were retrospectively enrolled." | 1.43 | Impact of diabetes mellitus on oncological outcomes after radical hysterectomy for early stage cervical cancer. ( Hanprasertpong, J; Jiamset, I, 2016) |
| "Female patients with type 2 diabetes at an onset age of 25-74 years during 1999-2005 and newly treated with metformin (n=132971, "ever users of metformin") or other antidiabetic drugs (n=6940, "never users of metformin") were followed for at least 6 months until December 31, 2011." | 1.43 | Metformin use and cervical cancer risk in female patients with type 2 diabetes. ( Tseng, CH, 2016) |
| "Metformin is a potential drug for the treatment of cervical cancers, in particular to those with intact LKB1 expression." | 1.38 | Metformin impairs the growth of liver kinase B1-intact cervical cancer cells. ( Chen, J; Cui, R; Davis, BC; He, Q; Liang, J; Lu, C; Werle, KD; Xiao, X; Xu, ZX; Zhao, RX, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 16 (64.00) | 24.3611 |
| 2020's | 9 (36.00) | 2.80 |
| Authors | Studies |
|---|---|
| Han, K | 2 |
| Fyles, A | 1 |
| Shek, T | 1 |
| Croke, J | 1 |
| Dhani, N | 1 |
| D'Souza, D | 1 |
| Lee, TY | 1 |
| Chaudary, N | 1 |
| Bruce, J | 1 |
| Pintilie, M | 2 |
| Cairns, R | 1 |
| Vines, D | 1 |
| Pakbaz, S | 1 |
| Jaffray, D | 1 |
| Metser, U | 1 |
| Rouzbahman, M | 1 |
| Milosevic, M | 1 |
| Koritzinsky, M | 1 |
| Lyng, H | 1 |
| Skipar, K | 1 |
| Hompland, T | 1 |
| Kim, HM | 1 |
| Kang, MJ | 1 |
| Song, SO | 1 |
| Beduk Esen, CS | 1 |
| Gedik, ME | 1 |
| Canpinar, H | 1 |
| Yedekci, FY | 1 |
| Yildiz, F | 1 |
| Gunaydin, G | 1 |
| Gultekin, M | 1 |
| Xia, C | 5 |
| Yang, F | 1 |
| He, Z | 4 |
| Cai, Y | 2 |
| Hakimee, H | 1 |
| Hutamekalin, P | 1 |
| Tanasawet, S | 1 |
| Chonpathompikunlert, P | 1 |
| Tipmanee, V | 1 |
| Sukketsiri, W | 1 |
| Liu, C | 1 |
| Chen, J | 4 |
| Chen, YH | 1 |
| Yang, SF | 1 |
| Yang, CK | 1 |
| Tsai, HD | 1 |
| Chen, TH | 1 |
| Chou, MC | 1 |
| Hsiao, YH | 1 |
| Clifford, RE | 1 |
| Gerrard, AD | 1 |
| Fok, M | 1 |
| Vimalachandran, D | 1 |
| Hoppe-Seyler, K | 1 |
| Herrmann, AL | 1 |
| Däschle, A | 1 |
| Kuhn, BJ | 1 |
| Strobel, TD | 1 |
| Lohrey, C | 1 |
| Bulkescher, J | 1 |
| Krijgsveld, J | 1 |
| Hoppe-Seyler, F | 1 |
| Liu, Y | 1 |
| Murray-Stewart, T | 1 |
| Casero, RA | 1 |
| Kagiampakis, I | 1 |
| Jin, L | 1 |
| Zhang, J | 1 |
| Wang, H | 1 |
| Che, Q | 1 |
| Tong, H | 1 |
| Ke, J | 1 |
| Jiang, F | 1 |
| Wang, F | 1 |
| Wan, X | 1 |
| Tyszka-Czochara, M | 3 |
| Bukowska-Strakova, K | 1 |
| Majka, M | 3 |
| Takiuchi, T | 1 |
| Machida, H | 1 |
| Hom, MS | 1 |
| Mostofizadeh, S | 1 |
| Frimer, M | 1 |
| Brunette, LL | 1 |
| Matsuo, K | 1 |
| Lasota, M | 1 |
| Liang, S | 2 |
| Zhu, X | 1 |
| Chen, R | 3 |
| Xu, W | 1 |
| Yang, J | 1 |
| Xiao, G | 2 |
| Jiang, S | 2 |
| Yudhani, RD | 1 |
| Astuti, I | 1 |
| Mustofa, M | 1 |
| Indarto, D | 1 |
| Muthmainah, M | 1 |
| Lipscombe, LL | 1 |
| Lega, IC | 1 |
| Milosevic, MF | 1 |
| Fyles, AW | 1 |
| Jiamset, I | 2 |
| Hanprasertpong, J | 2 |
| Tseng, CH | 1 |
| Geater, A | 1 |
| Peerawong, T | 1 |
| Hemman, W | 1 |
| Kornsilp, S | 1 |
| Cheng, K | 1 |
| Hao, M | 1 |
| Konieczny, P | 1 |
| Qi, Q | 1 |
| Pan, Y | 1 |
| Du, L | 1 |
| Xiao, X | 1 |
| He, Q | 1 |
| Lu, C | 1 |
| Werle, KD | 1 |
| Zhao, RX | 1 |
| Davis, BC | 1 |
| Cui, R | 1 |
| Liang, J | 1 |
| Xu, ZX | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Caffeic Acid for Advanced Esophageal Squamous Cell Cancer: A Randomized, Double-blind, and Multicenter Trial in Chinese Patients[NCT03070262] | Phase 3 | 300 participants (Anticipated) | Interventional | 2017-01-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for metformin and Uterine Cervical Neoplasms
| Article | Year |
|---|---|
Metformin as a radiosensitiser for pelvic malignancy: A systematic review of the literature.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Female; Humans; Hypoglycemic Agents; Male; Metformin; Ne | 2021 |
Metformin as a radiosensitiser for pelvic malignancy: A systematic review of the literature.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Female; Humans; Hypoglycemic Agents; Male; Metformin; Ne | 2021 |
1 trial available for metformin and Uterine Cervical Neoplasms
| Article | Year |
|---|---|
A Phase II Randomized Trial of Chemoradiation with or without Metformin in Locally Advanced Cervical Cancer.
Topics: COVID-19; Female; Humans; Hypoxia; Metformin; Nitroimidazoles; Pandemics; Positron Emission Tomograp | 2022 |
A Phase II Randomized Trial of Chemoradiation with or without Metformin in Locally Advanced Cervical Cancer.
Topics: COVID-19; Female; Humans; Hypoxia; Metformin; Nitroimidazoles; Pandemics; Positron Emission Tomograp | 2022 |
23 other studies available for metformin and Uterine Cervical Neoplasms
| Article | Year |
|---|---|
Targeted Therapy on the Screen: Do We Hit the Target?
Topics: Female; Humans; Hypoglycemic Agents; Metformin; Uterine Cervical Neoplasms | 2022 |
Targeted Therapy on the Screen: Do We Hit the Target?
Topics: Female; Humans; Hypoglycemic Agents; Metformin; Uterine Cervical Neoplasms | 2022 |
Metformin and Cervical Cancer Risk in Patients with Newly Diagnosed Type 2 Diabetes: A Population-Based Study in Korea.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Republic of | 2022 |
Metformin and Cervical Cancer Risk in Patients with Newly Diagnosed Type 2 Diabetes: A Population-Based Study in Korea.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Republic of | 2022 |
Radiosensitising Effects of Metformin Added to Concomitant Chemoradiotherapy with Cisplatin in Cervical Cancer.
Topics: AMP-Activated Protein Kinases; Apoptosis; Cell Line, Tumor; Chemoradiotherapy; Cisplatin; Female; He | 2023 |
Radiosensitising Effects of Metformin Added to Concomitant Chemoradiotherapy with Cisplatin in Cervical Cancer.
Topics: AMP-Activated Protein Kinases; Apoptosis; Cell Line, Tumor; Chemoradiotherapy; Cisplatin; Female; He | 2023 |
iTRAQ-based quantitative proteomic analysis of the inhibition of cervical cancer cell invasion and migration by metformin.
Topics: Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Female; HeLa Cells; Humans; Metformi | 2020 |
iTRAQ-based quantitative proteomic analysis of the inhibition of cervical cancer cell invasion and migration by metformin.
Topics: Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Female; HeLa Cells; Humans; Metformi | 2020 |
Metformin Inhibit Cervical Cancer Migration by Suppressing the FAK/Akt Signaling Pathway.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Female; Focal Adhesion Kinase 1; HeLa Cells; | 2019 |
Metformin Inhibit Cervical Cancer Migration by Suppressing the FAK/Akt Signaling Pathway.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Female; Focal Adhesion Kinase 1; HeLa Cells; | 2019 |
Metformin inhibits cervical cancer cell proliferation by modulating PI3K/Akt-induced major histocompatibility complex class I-related chain A gene expression.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Cell Movement; Cell Proliferation; Female; Gene Expression Re | 2020 |
Metformin inhibits cervical cancer cell proliferation by modulating PI3K/Akt-induced major histocompatibility complex class I-related chain A gene expression.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Cell Movement; Cell Proliferation; Female; Gene Expression Re | 2020 |
Metformin induces apoptosis and inhibits migration by activating the AMPK/p53 axis and suppressing PI3K/AKT signaling in human cervical cancer cells.
Topics: AMP-Activated Protein Kinases; Apoptosis; Cell Movement; Female; HeLa Cells; Humans; Metformin; Phos | 2021 |
Metformin induces apoptosis and inhibits migration by activating the AMPK/p53 axis and suppressing PI3K/AKT signaling in human cervical cancer cells.
Topics: AMP-Activated Protein Kinases; Apoptosis; Cell Movement; Female; HeLa Cells; Humans; Metformin; Phos | 2021 |
Effects of Metformin on the virus/host cell crosstalk in human papillomavirus-positive cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Cellular Senescence; Female | 2021 |
Effects of Metformin on the virus/host cell crosstalk in human papillomavirus-positive cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Cellular Senescence; Female | 2021 |
Targeting hexokinase 2 inhibition promotes radiosensitization in HPV16 E7-induced cervical cancer and suppresses tumor growth.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Glu | 2017 |
Targeting hexokinase 2 inhibition promotes radiosensitization in HPV16 E7-induced cervical cancer and suppresses tumor growth.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Glu | 2017 |
Metformin and caffeic acid regulate metabolic reprogramming in human cervical carcinoma SiHa/HTB-35 cells and augment anticancer activity of Cisplatin via cell cycle regulation.
Topics: Antineoplastic Agents; Caffeic Acids; Cell Cycle; Cell Line, Tumor; Cisplatin; Drug Synergism; Drug | 2017 |
Metformin and caffeic acid regulate metabolic reprogramming in human cervical carcinoma SiHa/HTB-35 cells and augment anticancer activity of Cisplatin via cell cycle regulation.
Topics: Antineoplastic Agents; Caffeic Acids; Cell Cycle; Cell Line, Tumor; Cisplatin; Drug Synergism; Drug | 2017 |
Association of Metformin Use and Survival Outcome in Women With Cervical Cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Female; Humans; Metformin; Mi | 2017 |
Association of Metformin Use and Survival Outcome in Women With Cervical Cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Female; Humans; Metformin; Mi | 2017 |
Caffeic Acid and Metformin Inhibit Invasive Phenotype Induced by TGF-β1 in C-4I and HTB-35/SiHa Human Cervical Squamous Carcinoma Cells by Acting on Different Molecular Targets.
Topics: Biomarkers, Tumor; Caffeic Acids; Carbonic Anhydrase IX; Carcinoma, Squamous Cell; Cell Adhesion; Ce | 2018 |
Caffeic Acid and Metformin Inhibit Invasive Phenotype Induced by TGF-β1 in C-4I and HTB-35/SiHa Human Cervical Squamous Carcinoma Cells by Acting on Different Molecular Targets.
Topics: Biomarkers, Tumor; Caffeic Acids; Carbonic Anhydrase IX; Carcinoma, Squamous Cell; Cell Adhesion; Ce | 2018 |
Metformin, a first-line drug for type 2 diabetes mellitus, disrupts the MALAT1/miR-142-3p sponge to decrease invasion and migration in cervical cancer cells.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Diabetes M | 2018 |
Metformin, a first-line drug for type 2 diabetes mellitus, disrupts the MALAT1/miR-142-3p sponge to decrease invasion and migration in cervical cancer cells.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Diabetes M | 2018 |
Metformin combined with nelfinavir induces SIRT3/mROS-dependent autophagy in human cervical cancer cells and xenograft in nude mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Female; HeLa Cells; HIV Protease | 2019 |
Metformin combined with nelfinavir induces SIRT3/mROS-dependent autophagy in human cervical cancer cells and xenograft in nude mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Female; HeLa Cells; HIV Protease | 2019 |
Metformin Modulates Cyclin D1 and P53 Expression to Inhibit Cell Proliferation and to Induce Apoptosis in Cervical Cancer Cell Lines.
Topics: Apoptosis; Cell Proliferation; Cyclin D1; Female; Gene Expression Regulation, Neoplastic; HeLa Cells | 2019 |
Metformin Modulates Cyclin D1 and P53 Expression to Inhibit Cell Proliferation and to Induce Apoptosis in Cervical Cancer Cell Lines.
Topics: Apoptosis; Cell Proliferation; Cyclin D1; Female; Gene Expression Regulation, Neoplastic; HeLa Cells | 2019 |
Association between Metformin Use and Mortality after Cervical Cancer in Older Women with Diabetes.
Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Metformin; Ret | 2016 |
Association between Metformin Use and Mortality after Cervical Cancer in Older Women with Diabetes.
Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Metformin; Ret | 2016 |
Impact of diabetes mellitus on oncological outcomes after radical hysterectomy for early stage cervical cancer.
Topics: Adult; Age Factors; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Hysterectomy; Me | 2016 |
Impact of diabetes mellitus on oncological outcomes after radical hysterectomy for early stage cervical cancer.
Topics: Adult; Age Factors; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Hysterectomy; Me | 2016 |
Metformin use and cervical cancer risk in female patients with type 2 diabetes.
Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Incidence; Met | 2016 |
Metformin use and cervical cancer risk in female patients with type 2 diabetes.
Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Incidence; Met | 2016 |
The Effect of Metformin on Oncological Outcomes in Patients With Cervical Cancer With Type 2 Diabetes Mellitus.
Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Metformin; Mid | 2017 |
The Effect of Metformin on Oncological Outcomes in Patients With Cervical Cancer With Type 2 Diabetes Mellitus.
Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Metformin; Mid | 2017 |
Metformin Inhibits TGF-β1-Induced Epithelial-to-Mesenchymal Transition via PKM2 Relative-mTOR/p70s6k Signaling Pathway in Cervical Carcinoma Cells.
Topics: Carrier Proteins; Cell Movement; Cell Proliferation; Cell Survival; Epithelial-Mesenchymal Transitio | 2016 |
Metformin Inhibits TGF-β1-Induced Epithelial-to-Mesenchymal Transition via PKM2 Relative-mTOR/p70s6k Signaling Pathway in Cervical Carcinoma Cells.
Topics: Carrier Proteins; Cell Movement; Cell Proliferation; Cell Survival; Epithelial-Mesenchymal Transitio | 2016 |
Caffeic Acid Expands Anti-Tumor Effect of Metformin in Human Metastatic Cervical Carcinoma HTB-34 Cells: Implications of AMPK Activation and Impairment of Fatty Acids De Novo Biosynthesis.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Caffeic Acids; Cell Cycle; Cell Lin | 2017 |
Caffeic Acid Expands Anti-Tumor Effect of Metformin in Human Metastatic Cervical Carcinoma HTB-34 Cells: Implications of AMPK Activation and Impairment of Fatty Acids De Novo Biosynthesis.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Caffeic Acids; Cell Cycle; Cell Lin | 2017 |
Combining metformin and nelfinavir exhibits synergistic effects against the growth of human cervical cancer cells and xenograft in nude mice.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergism; | 2017 |
Combining metformin and nelfinavir exhibits synergistic effects against the growth of human cervical cancer cells and xenograft in nude mice.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergism; | 2017 |
Metformin impairs the growth of liver kinase B1-intact cervical cancer cells.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Apoptosis; Autophagy; Cell Grow | 2012 |
Metformin impairs the growth of liver kinase B1-intact cervical cancer cells.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Apoptosis; Autophagy; Cell Grow | 2012 |